Lupin Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for OralSuspension.".
Press Release Jul 04 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Press Release Jul 03 2023
- Press Release Jun 29 2023
- Press Release Jun 23 2023
- Press Release (Revised) Jun 21 2023
- Press Release Jun 21 2023
Later from Lupin
- Press Release Jul 11 2023
- Press Release Jul 14 2023
- Press Release Jul 21 2023
- Press Release Jul 24 2023
- Press Release Jul 26 2023
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin